Trial Profile
XIENCE V Everolimus Eluting Coronary Stent System (EECSS) China: Post-Approval, Single-Arm Study
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 08 Nov 2021
Price :
$35
*
At a glance
- Drugs Everolimus (Primary)
- Indications Coronary artery disease; Coronary artery restenosis
- Focus Therapeutic Use
- Acronyms XIENCE V China; XV CHINA SAS
- Sponsors Abbott Laboratories
- 18 Mar 2019 Results of a pooled analysis of the four XIENCE Post-Approval Trials assessing the impact of Renal Function in Patients With High Bleeding Risk Who Underwent Percutaneous Coronary Intervention With XIENCE, presented at the 68th Annual Scientific Session of the American College of Cardiology
- 24 Oct 2018 Status changed from active, no longer recruiting to completed.
- 25 Sep 2018 Results of a pooled analysis from XIENCEV USA, XIENCEV Japan, XIENCE V China and XIENCE V India trials presented at the 30th Annual Scientific Symposium on Transcatheter Cardiovascular Therapeutics